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Background: Healthcare expenditures in the United States exceed the healthcare expenditures of other countries, yet relatively
unfavorable health outcomes persist. Despite the emergence of numerous evidence-based interventions, wide variations in
clinical care have caused disparities in quality of care and cost. Comparative effectiveness and cost effectiveness research may
better guide healthcare decisionmakers in determining which interventions work best, for which populations, under which
conditions, and at what cost.
Methods: This article reviews national health policies that promote comparative effectiveness research (CER), healthcare
decisionmaker roles in CER, methodological approaches to CER, and future implications of CER.
Results: This article provides a brief summary of CER health policy up to the Patient Protection and Affordable Care Act and its
establishment of the Patient-Centered Outcomes Research Institute (PCORI). Through PCORI, participatory methods for
engaging healthcare decisionmakers in the entire CER process have gained momentum as a strategy for improving the
relevance of research and expediting the translation of research into practice. Well-designed, methodologically rigorous
observational studies and randomized trials conducted in real-world settings have the potential to improve the quality,
generalizability, and transferability of study findings.
Conclusion: Learning health systems and practice-based research networks provide the infrastructure for advancing CER
methods, generating local solutions to high-quality cost-effective care, and transitioning research into implementation and
dissemination science—all of which will ultimately guide health policy on clinical care, payment for care, and population health.
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INTRODUCTION
Per capita healthcare spending in the United States
continues to be among the highest in the world; however,
this investment has not translated into better health
outcomes compared to other high-income countries.1 Wide
variations in treatments, outcomes, and costs clearly indicate
a need for improvement in the US healthcare system. These
problems are fueling demands from healthcare decision-
makers for more evidence of the comparative effectiveness
and cost effectiveness of medical interventions.
Comparative effectiveness research (CER) is believed to
be the mechanism that will fill current knowledge gaps in
healthcare decisionmaking.2-3 The Institute of Medicine
(IOM) National Priorities Committee defines CER as ‘‘the
generation and synthesis of evidence that compares the
benefits and harms of alternative methods to prevent,
diagnose, treat, and monitor a clinical condition or to
improve the delivery of care.’’2 The purpose of CER is to
‘‘assist consumers, clinicians, purchasers, and policy
makers to make informed decisions that will improve
healthcare at both the individual and population levels.’’2
The IOM further emphasizes the need to directly compare
alternative interventions, study patients in real-world clinical
settings, and strive to tailor medical decisions to individual
(or subgroup) values and preferences.
Given the increased prominence of CER for healthcare
decisionmaking, this article provides a brief overview of the
(1) historic context of national health policies supporting
CER; (2) role of healthcare stakeholder engagement in
CER; (3) methodological considerations in the conduct of
CER; and (4) future implications for research, clinical
practice, and health policy.
LITERATURE SEARCH
The author searched PubMed for methodological guide-
lines and publishing standards for CER using the following
search strategy: (comparative effectiveness research [MeSH
Terms] OR (comparative [All Fields] AND effectiveness [All
Fields] AND research [All Fields]) OR comparative effective-
ness research [All Fields]). The search, limited to review
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articles published between 2009 and 2014, yielded 941
articles. The search was further restricted to articles with the
search terms in the title, yielding 20 articles. From these
articles, the author selected general reviews on research
methodology and standards for reporting and then searched
PubMed for related articles. The author also searched the
reference lists of articles identified as key references to find
additional articles. The author employed the same search
strategy to identify key reference articles that discussed CER
within the context of thePatient ProtectionandAffordableCare
Act (PPACA) and stakeholder engagement. Table 1 provides
an overview of the key findings of this review process.
HEALTH POLICIES
After passage of the Social Security Amendments of 1965
that established Medicare and Medicaid, health services
research became especially important to Congress as the
members of the House of Representatives and Senate
struggled to figure out how to contain rising healthcare
expenditures.4 In 1999, Congress established the Agency for
Healthcare Research and Quality (AHRQ) that was tasked
with examining (1) outcomes, effectiveness, and cost
effectiveness of medical practices and technologies; (2)
utilization and access to care; (3) organization, delivery, and
financing of services and their interaction with and impact on
quality of care; (4) methods for measuring and strategies for
improving quality of care; (5) strategies for engaging patients
in their care; and (6) methods by which healthcare
stakeholders learn best practices and use this information
for healthcare delivery.5,6 In 2003, the Medicare Prescription
Drug, Improvement, and Modernization Act created the
Effective Health Care Program to expand AHRQ’s responsi-
Table 1. Summary of Comparative Effectiveness Research
Comparative effectiveness research (CER) Patient Protection and Affordable Care Act definition:
‘‘Research evaluation and comparing health outcomes and clinical
effectiveness, risks, and benefits of two or more medical treatments,
services, and items’’
Treatments, services, and items definition:
‘‘healthcare interventions; protocols for treatment, care management, and
delivery; procedures; medical devices; diagnostic tools; pharmaceuticals;
integrative health practices; any other strategies or items being used in
the treatment, management, and diagnosis, or prevention of, illness or
injury in individuals’’4,7
Patient-centered outcomes research Patient-Centered Outcomes Research Institute (PCORI) definition:
 Compares alternative approaches to clinical management
 Engages patients and key stakeholders throughout the research process
 Assesses outcomes that are meaningful to patients
 Implements research findings in clinical settings8
PCORI engagement principles  Reciprocal relationships
 Colearning
 Partnership
 Trust/transparency/honesty
Healthcare stakeholders  Patients and the general public
 Providers
 Purchasers
 Payers
 Policy makers
 Product makers
 Principal investigators
Major CER study designs  Randomized clinical trials (cluster, pragmatic, adaptive)
 Prospective observational studies
 Retrospective observational studies
Clinical practice settings for CER  Learning health systems
 Practice-based research networks
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bility to include CER.4 In 2009, the American Recovery and
Reinvestment Act appropriated $1.1 billion for CER and
tasked the IOM with establishing research priorities. The IOM
subsequently recommended 100 CER priorities—many of
which focus on the need to improve health service delivery.2
The PPACA moved the United States toward a national
policy for CER to increase accountability for quality and cost
of care. The PPACA established the Patient-Centered
Outcomes Research Institute (PCORI) as a government-
sponsored nonprofit organization to advance the quality
and relevance of clinical evidence that patients, clinicians,
health insurers, and policy makers can use to make
informed decisions.4 PCORI’s funding source is the Pa-
tient-Centered Outcomes Research Trust Fund that receives
funding from the Federal Hospital Insurance Trust Fund, the
Federal Supplementary Medical Insurance Trust Fund, the
Treasury general fund, and fees on health plans to support
CER.7 The PPACA defines CER as ‘‘research evaluation and
comparing health outcomes and clinical effectiveness, risks,
and benefits of two or more medical treatments, services,
and items.’’4,7 The PPACA defines treatment, services, and
items as ‘‘healthcare interventions; protocols for treatment,
care management, and delivery; procedures; medical
devices; diagnostic tools; pharmaceuticals; integrative
health practices; any other strategies or items being used
in the treatment, management, and diagnosis, or prevention
of, illness or injury in individuals.’’4,7 The law further
specifies that PCORI must ensure that CER accounts for
differences in key subpopulations (eg, race/ethnicity,
gender, age, and comorbidity) to increase the relevance
of the research.
PCORI formally incorporated the concept of ‘‘patient-
centeredness’’ into CER and characterized patient-centered
outcomes research (PCOR) as (1) comparing alternative
approaches to clinical management, (2) actively engaging
patients and key stakeholders throughout the research
process, (3) assessing outcomes that are meaningful to
patients, and (4) implementing research findings in clinical
settings.8 Examining the impact of interventions on patient-
reported outcome measures such as symptom severity,
functional status, and quality of life is an imperative
component of PCOR. The best way to determine which
outcomes matter most to patients and their caregivers is to
engage them in the research process.
STAKEHOLDER ENGAGEMENT
Engaging stakeholders in research improves the rele-
vance of study questions, increases transparency, enhanc-
es study implementation, and accelerates the adoption of
research findings into practice and health policy.9 The
degree of stakeholder participation depends on interest,
expertise, negotiation, and/or project governance structure.
Stakeholders are categorized into 7 groups, including
patients and the public, providers (individuals or organiza-
tions), purchasers (responsible for underwriting costs of
care), payers (responsible for reimbursement), policy
makers, product makers (drug/device manufacturers), and
principal investigators (researchers or their funders).10 Two
2014 reviews of stakeholder engagement in CER and PCOR
demonstrate that patients are the most frequently engaged
stakeholder group, engagement most often occurs in the
early stages of research (prioritization), and stakeholder
roles in research are highly variable.10,11 Engagement
strategies range from surveys, focus groups, and interviews
to participation in study advisory boards or research teams.
No clear evidence supports any particular strategy for
engaging patient stakeholders as better than others.11
The PCORI Patient and Family Engagement Rubric
describes stakeholder engagement in the study planning,
study implementation, and dissemination of results for CER
and PCOR.12 The rubric is not intended to be comprehen-
sive or prescriptive. However, it outlines 4 PCOR engage-
ment principles: (1) reciprocal relationships (clearly outlining
the roles of all research partners, including patients); (2)
colearning (a bidirectional process in which patient partners
understand the research process and researchers under-
stand the principles of patient-centeredness and engage-
ment); (3) partnership (fair financial compensation,
thoughtful consideration for the time commitment request-
ed, and accommodation for cultural diversity); and (4)
trust/transparency/honesty (inclusive decisionmaking, shar-
ing information with all partners, commitment to open and
honest communication, and communicating study findings
in meaningful and usable ways).12
METHODOLOGICAL CONSIDERATIONS
Study Designs
Although CER and PCOR utilize participatory approaches
to research, stakeholder engagement does not preclude the
need to employ the methodological rigor of research.
Careful attention to study design is imperative. The principal
methods for CER are observational studies (prospective
and retrospective), randomized trials, decision analysis, and
systematic reviews.13 Table 2 summarizes 3 studies that
employ the 2 main forms of CER—randomized trials and
observational studies. The Adherence and Intensification of
Medications (AIM) study demonstrates the value of con-
ducting randomized controlled pragmatic trials.14 The
Swedish Obese Subjects (SOS) trial is one of the largest
prospective observational cohort studies to date.15 The
Initial Choice of Glucose-Lowering Medication for Diabetes
Mellitus study used insurance claims data for a retrospec-
tive cohort study.16
The advantage of observational studies is that they can
quickly provide low-cost, large study populations. Observa-
tional studies also include data from diverse patients
obtained during routine clinical practice that strengthen
the external generalizability of study findings. Nonetheless,
observational studies are limited by the inherent bias and
confounding of results that routinely occur in nonrandom-
ized studies.13,17,18 To minimize the threats to the internal
validity of observational studies, research guidelines rec-
ommend the following: a priori specification of research
questions, targeted patient populations, comparative inter-
ventions, and postulated confounders; selection of study
designs that are appropriate to the study questions;
selection of the appropriate data source; and transparency
in protocol development and prespecified analytic
plans.18,19 A discussion of analytic methods (regression
analysis, propensity scores, sensitivity analysis, instrumen-
tal variables, and structural model equations) for observa-
tional studies is beyond the scope of this article, but these
methods are discussed in detail in several reviews of
CER.13,17,18
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The International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) Good Research Practices Task
Force provides detailed recommendations on how to
determine when to do a prospective vs retrospective study,
the advantages and disadvantages of different study designs,
and analytic approaches to consider in study execution.18,19
Several designs have been developed for prospective
observational studies.18 The single group, pretest/posttest
design is a longitudinal study in which subjects serve as their
own control, and outcomes are collected before and after an
intervention. In contrast, the multiple group, pretest/posttest
design collects outcomes for at least 2 comparison groups.
The multiple group, cross-sectional design involves study
participants with a particular condition who have already
undergone one of multiple interventions. Prospective cohort
studies are longitudinal studies in which outcomes are only
collected after an intervention.
The ISPOR task force also provides guidelines for
conducting retrospective observational studies on second-
ary data sources (eg, claims databases and electronic
medical records).19 Electronic databases contain informa-
tion collected for operational reasons rather than research
purposes and therefore have minimal reporting bias.
However, data quality (eg, missing/incomplete data),
selection bias, and unmeasured confounding inherent to
data collected in clinical practice are major threats to
internal validity. Careful attention to the epidemiologic study
design (cross-sectional, cohort, case-control, case-cross-
over) and statistical methods is critical to enhancing study
validity. Cross-sectional studies provide a snapshot of data
but limit the ability to establish the temporality of exposure
to an intervention relative to the outcome of interest. When
temporality of exposure is of particular interest, cohort
studies are ideal. Case-control designs are historically
helpful when the outcome of interest is rare. The case-
crossover design, in which individuals serve as their own
control, is ideal when transient exposures result in acute
events or outcomes. Retrospective studies, if done well, can
supplement evidence from prospective observational stud-
ies and randomized trials.
While the more costly traditional randomized controlled
trials (RCTs) have the advantage of strong internal validity,
their restrictive inclusion criteria tend to result in homoge-
nous groups of study participants that are not reflective of
what clinicians see in real practice. For cost reasons, RCTs
are often limited in size (limiting the ability to detect adverse
effects) and in duration (limiting the ability to observe long-
term outcomes).
RCTs require large populations to implement the key
elements of CER as defined by the IOM (comparison of
alternative interventions in real-world settings and tailored to
the values of individuals or subpopulations) and to avoid
false conclusions.13 Cluster randomized trials meet the CER
criteria of direct comparison of interventions because
randomization occurs at the practice level instead of the
individual patient level. Implementation of a single interven-
tion at a site resembles what happens in real practice.
Pragmatic or practical trials examine interventions that are
currently in use in typical practice settings and include
patients with demographic profiles that are similar to
patients routinely treated in real practice.3,13,20,21 The major
drawback to pragmatic trials is that they usually require
larger sample sizes and longer follow-ups of major clinical
outcomes compared to traditional RCTs to better reflect the
natural history of disease. To minimize costs, pragmatic
trials may limit outcome measurements to easily obtained
data.13 Doing so, however, may result in not collecting
cause-specific measures, thus limiting the ability to ascer-
tain why an intervention is or is not effective. Adaptive trials
change design in response to prespecified criteria and
study data collected that may reveal early indications of a
study’s ultimate outcomes.13 The changes can occur in any
aspect of the study—the number of arms, types of
intervention, sample sizes, sampling strategy for subgroups
of interest, or outcome measures. Adaptive changes
maximize study efficiency and increase relevance.
Regardless of which study design is employed (observa-
tional or randomized trial), transparency and adherence to
methodological standards will enhance generalizability and
transferability of study results across populations, settings,
and systems of care. A number of research guidelines are
available to help investigators appropriately plan and
execute methodologically rigorous CER studies.13,17-19,22-28
Integrating Research in Clinical Practice
To expand CER, researchers must have conducive
practice environments in which to conduct studies. Learning
health systems and practice-based research networks may
be uniquely positioned to meet the infrastructure needs of
CER because they are positioned to promote research
prioritization, evidence generation, and translation of evi-
dence into practice.29-31
In learning health systems, research and clinical practice
are tightly integrated; thus research priorities are aligned
with key issues clinicians face in everyday practice, and
research on those issues informs best practice.21 Key
attributes of learning health systems include proactively
identifying problems to guide research priorities, testing
pilot interventions to identify strategies for successfully
implementing interventions in diverse settings, evaluating
interventions with predefined impact measures, adjusting
interventions to the contextual environment, and dissemi-
nating findings internally and externally.32 Learning health
systems such as hospital-based CER centers may be the
ideal model for improving evidence-based practice and cost
containment.33 Hospital-based CER can harness local data
on utilization, outcomes, and cost of care from electronic
medical records and other data warehouses to identify gaps
in service or practice. To close the gap, clinical decision
support and quality improvement initiatives can be integrat-
ed into the health system while using administrative and
clinical data to monitor performance.
Practice-based research networks (PBRNs) are organized
networks of ambulatory practices involved in primary care
research. According to the AHRQ, ‘‘PBRNs draw on the
experience and insight of practicing clinicians to identify and
frame research questions whose answers can improve the
practice of primary care. By linking these questions with
rigorous research methods, the PBRN can produce re-
search findings that are immediately relevant to the clinician
and, in theory, more easily assimilated into everyday
practice.’’34 As of July 2012, the AHRQ reported that of
the 136 PBRNs in the United States, 15% were national and
28% were regional network collaborations.35 Greater exter-
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nal generalizability of study results from these large
networks is the obvious advantage. PBRNs are especially
attractive for recruiting priority patient populations that are
often underrepresented in clinical research (eg, multiple
chronic conditions) and for collecting comprehensive data
on patient-reported outcomes, practice settings, and con-
textual factors that affect healthcare decisionmaking.31
Research in PBRNs is usually aligned with quality improve-
ment activities increasingly using participatory methods to
not only make the research relevant but also to improve the
translation of research into practice.36 PBRNs are rapidly
evolving into learning collaboratives, given the nature of the
research and various engagement strategies.
FUTURE IMPLICATIONS
Improving the quality and relevance of evidence on the
clinical effectiveness of healthcare services holds promise
for shaping policies related to clinical care, payment for
services, and population health. Increased emphasis on
implementation science to accelerate the use of evidence-
based interventions in clinical practice is needed.37 Partic-
ipatory research methods are likely to produce evidence-
based interventions that are more relevant and actionable to
healthcare decisionmakers compared to nonparticipatory
research. Healthcare organizations can advance CER by
investing in (1) personnel dedicated to data collection,
monitoring, and interpretation; (2) data infrastructure and
analytics; (3) evidence-based quality improvement initia-
tives; and (4) adaptive implementation and dissemination
strategies.38 A systems approach to implementing evi-
dence-based interventions in research is necessary to
account for the dynamic, complex environments in which
patient care occurs.37
CONCLUSION
Broadening approaches to research whereby investiga-
tors use study designs that best match research questions
rather than limiting discovery research to randomized trials
is critical to advancing CER. Prospective, practice-based
studies will help clarify the resources needed to implement
evidence-based interventions and identify which interven-
tions work best for specific populations and settings. Given
the connection between local healthcare delivery and
national healthcare expenditures, any local knowledge
gained from CER in learning health systems and PBRNs
automatically has implications for national health policy.
ACKNOWLEDGMENTS
The author has no financial or proprietary interest in the
subject matter of this article.
REFERENCES
1. Moses H 3rd, Matheson DH, Dorsey ER, George BP, Sadoff D,
Yoshimura S. The anatomy of health care in the United States.
JAMA. 2013 Nov 13;310(18):1947-1963.
2. Institute of Medicine. Initial National Priorities for Comparative
Effectiveness Research. Washington, DC: National Academies
Press; 2009. http://books.nap.edu/openbook.
php?record_id¼12648. Accessed September 25, 2014.
3. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing
the value of clinical research for decision making in clinical and
health policy. JAMA. 2003 Sep 24;290(12):1624-1632.
4. Kinney ED. Comparative effectiveness research under the Patient
Protection and Affordable Care Act: can new bottles
accommodate old wine? Am J Law Med. 2011;37(4):522-566.
5. Healthcare Research and Quality Act of 1999, Pub L No. 106-129.
https://www.congress.gov/bill/106th-congress/senate-bill/580.
Accessed November 28, 2014.
6. Agency for Healthcare Research and Quality: General
Provisions—Definitions, 42 USC §299-299c-7 (2010). http://
uscode.house.gov/browse/prelim@title42/
chapter6A&edition¼prelim. Accessed November 28, 2014.
7. Thorpe JH. Comparative effectiveness research and health
reform: implications for public health policy and practice. Public
Health Rep. 2010 Nov-Dec;125(6):909-912.
8. Hickam D, Slutsky J. PCORI funding announcements (PFAs),
methodology standards, and national priorities. Presented at:
Getting to Know PCORI: From Application to Closeout [PCORI
workshop]; September 22-23, 2014; San Diego, CA. http://www.
pcori.org/sites/default/files/PCORI-Getting-To-Know-PCORI-Work
shop_PFA-Methodology-Standards-and-National-Priorities_0922
14.pdf. Accessed November 28, 2014.
9. Cargo M, Mercer SL. The value and challenges of participatory
research: strengthening its practice. Annu Rev Public Health. 2008;
29:325-350.
10. Concannon TW, Fuster M, Saunders T, et al. A systematic review
of stakeholder engagement in comparative effectiveness and
patient-centered outcomes research. J Gen Intern Med. 2014 Dec;
29(12):1692-1701.
11. Domecq JP, Prutsky G, Elraiyah T, et al. Patient engagement in
research: a systematic review. BMC Health Serv Res. 2014 Feb 26;
14:89.
12. Patient Centered Outcome Research Institute. PCORI Patient and
Family Engagement Rubric. http://www.pcori.org/assets/2014/
02/PCORI-Patient-and-Family-Engagement-Rubric.pdf. February
3, 2014. Accessed November 28, 2014.
13. Sox HC, Goodman SN. The methods of comparative effectiveness
research. Annu Rev Public Health. 2012 Apr;33:425-445.
14. Heisler M, Hofer TP, Schmittdiel JA, et al. Improving blood
pressure control through a clinical pharmacist outreach program
in patients with diabetes mellitus in 2 high-performing health
systems: the adherence and intensification of medications cluster
randomized, controlled pragmatic trial. Circulation. 2012 Jun 12;
125(23):2863-2872.
15. Sjo¨stro¨m L. Review of the key results from the Swedish Obese
Subjects (SOS) trial—a prospective controlled intervention study
of bariatric surgery. J Intern Med. 2013 Mar;273(3):
219-234.
16. Berkowitz SA, Krumme AA, Avorn J, et al. Initial choice of oral
glucose-lowering medication for diabetes mellitus: a patient-
centered comparative effectiveness study. JAMA Intern Med.
Epub 2014 Oct 27. doi:10.1001/jamainternmed.2014.5294.
17. Schneeweiss S. Developments in post-marketing comparative
effectiveness research. Clin Pharmacol Ther. 2007 Aug;82(2):143-156.
18. Berger ML, Dreyer N, Anderson F, Towse A, Sedrakyan A,
Normand SL. Prospective observational studies to assess
comparative effectiveness: the ISPOR good research practices
task force report. Value Health. 2012 Mar-Apr;15(2):217-230.
19. Berger ML, Mamdani M, Atkins D, Johnson ML. Good research
practices for comparative effectiveness research: defining,
reporting and interpreting nonrandomized studies of treatment
effects using secondary data sources: the ISPOR Good Research
Practices for Retrospective Database Analysis Task Force
Report—Part I. Value Health. 2009 Nov-Dec;12(8):1044-1052.
20. Chalkidou K, Tunis S, Whicher D, Fowler R, Zwarenstein M. The
role for pragmatic randomized controlled trials (pRCTs) in
comparative effectiveness research. Clin Trials. 2012 Aug;9(4):
436-446.
160 The Ochsner Journal
Comparative Effectiveness Research
21. Rosenthal GE. The role of pragmatic clinical trials in the evolution
of learning health systems. Trans Am Clin Climatol Assoc. 2014;
125:204-216; discussion 217-218.
22. Luce BR, Drummond MF, Dubois RW, et al. Principles for planning
and conducting comparative effectiveness research. J Comp Eff
Res. 2012 Sep;1(5):431-440.
23. Berger ML, Martin BC, Husereau D, et al. A questionnaire to
assess the relevance and credibility of observational studies to
inform health care decision making: an ISPOR-AMCP-NPC Good
Practice Task Force report. Value Health. 2014 Mar;17(2):
143-156. Erratum in: Value Health. 2014 Jun;17(4):489.
24. Dreyer NA, Schneeweiss S, McNeil BJ, et al. GRACE principles:
recognizing high-quality observational studies of comparative
effectiveness. Am J Manag Care. 2010 Jun;16(6):467-471.
25. Schneeweiss S. On guidelines for comparative effectiveness
research using nonrandomized studies in secondary data
sources. Value Health. 2009 Nov-Dec;12(8):1041.
26. Schneeweiss S, Seeger JD, Jackson JW, Smith SR. Methods for
comparative effectiveness research/patient-centered outcomes
research: from efficacy to effectiveness. J Clin Epidemiol. 2013
Aug;66(8 Suppl):S1-S4.
27. Glasgow RE, Magid DJ, Beck A, Ritzwoller D, Estabrooks PA.
Practical clinical trials for translating research to practice: design
and measurement recommendations. Med Care. 2005 Jun;43(6):
551-557.
28. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-
explanatory continuum indicator summary (PRECIS): a tool to
help trial designers. J Clin Epidemiol. 2009 May;62(5):464-475.
29. Grossmann C, Sanders J, English RA. Large Simple Trials and
Knowledge Generation in a Learning Health System: Workshop
Summary. Roundtable on Value & Science-driven Health Care,
Forum on Drug Discovery, Development, and Translation,
Institute of Medicine. The Learning Health Systems Series.
Washington, DC: National Academies Press; 2013. http://www.
ncbi.nlm.nih.gov/books/NBK201274/. Accessed November 28,
2014.
30. Saag KG, Mohr PE, Esmail L, et al. Improving the efficiency
and effectiveness of pragmatic clinical trials in older adults in
the United States. Contemp Clin Trials. 2012 Nov;33(6):1211-
1216.
31. Hartung DM, Guise JM, Fagnan LJ, Davis MM, Stange KC. Role of
practice-based research networks in comparative effectiveness
research. J Comp Eff Res. 2012 Jan;1(1):45-55.
32. Greene SM, Reid RJ, Larson EB. Implementing the learning health
system: from concept to action. Ann Intern Med. 2012 Aug 7;
157(3):207-210.
33. Umscheid CA, Williams K, Brennan PJ. Hospital-based
comparative effectiveness centers: translating research into
practice to improve the quality, safety and value of patient care. J
Gen Intern Med. 2010 Dec;25(12):1352-1355.
34. Agency for Healthcare Research and Quality. About. AHRQ
Practice-based Research Networks (PBRNs) website. http://pbrn.
ahrq.gov/about. Updated May 2013. Accessed November 28,
2014.
35. Agency for Healthcare Research and Quality. PBRN Slides. AHRQ
Practice-based Research Networks (PBRNs) website. http://pbrn.
ahrq.gov/pbrn-registry/pbrn-slides. Updated January 2014.
Accessed November 28, 2014.
36. Mold JW, Peterson KA. Primary care practice-based research
networks: working at the interface between research and
quality improvement. Ann Fam Med. 2005 May-Jun;3 (Suppl 1):
S12-S20.
37. Lobb R, Colditz GA. Implementation science and its
application to population health. Annu Rev Public Health. 2013;
34:235-251.
38. Masica AL, Ballard DJ. The protean role of health care delivery
organizations in comparative effectiveness research. Mayo Clin
Proc. 2009 Dec;84(12):1062-1064.
This article meets the Accreditation Council for Graduate Medical Education and the American Board of Medical
Specialties Maintenance of Certification competencies for Medical Knowledge and Systems-Based Practice.
Volume 15, Number 2, Summer 2015 161
Price-Haywood, EG
